In regard to the role of CD32+ B-cells in human Chagas disease, it has been demonstrated that patients with asymptomatic clinical forms present lower levels of these modulatory CD32 surface marker with concomitant higher antibody levels, whereas cardiac patients presented baseline expression of CD32 by B-cells with lower antibody titers. This evidence concerns the gene FCGR2A and Chagas disease.